Company intelligence / Profile preview

Soleno Therapeutics

Redwood City, California, United Statessoleno.life ↗

Ownership: Public · SLNO
Employees: ~92
Development stage: Other

Overview

Soleno’s lead program, VYKAT XR (diazoxide choline extended-release tablets; formerly DCCR), received FDA approval in April 2025 for the treatment of hyperphagia associated with Prader-Willi syndrome in adults and children aged four years and older. The company has initiated commercial launch activities in the U.S., with over 268 patient start forms received within weeks of launch. A Marketing Authorization Application to the European Medicines Agency for DCCR/VYKAT XR was planned for Q2 2025[6]. Clinical data presented at ISPOR 2025 highlighted significant reductions in hyperphagia and favorable safety outcomes[8].

Therapeutic areas: Rare DiseasesEndocrinology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

diazoxide choline extended-release

Approved

Partnerships

None disclosed as major pharmaceutical or biotech partnerships as of June 2025.

Beyond the preview

Go deeper on Soleno Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Soleno Therapeutics.